We report long-term outcome in 102 patients with cCML transplanted from an HLA-identical sibling donor from 1982 to 1998. The conditioning regimen was based on cyclophosphamide associated with either total body irradiation (TBI) (37 patients) or with busulfan (63 patients). Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporin and methotrexate in the majority of the patients. Fifteen year overall survival was estimated at 53% (95% confidence interval (CI), 44-65) with a plateau after 2.5 years. Long-term survival was adversely affected by: longer time from chronic myeloid leukemia (CML) diagnosis to transplantation, older age at time of transplantation and GvHD (acute grade III-IV or chronic extensive). The main cause of death was infection, related to GvHD in 69% of patients. Splenectomy also significantly increased the risk of bacterial infection. 15-year relapse was estimated at 8% (95% CI, 0.1-14). Late malignancies occurred in seven patients, four of whom had an invasive cancer. Other frequent late complications included cataracts, psychological depression, osteonecrosis and hypothyroidism. These complications were more frequent following splenectomy, TBI and in patients with chronic extensive GvHD. We conclude that allogeneic transplantation with a related donor can cure more than half of CML patients in chronic phase, although physicians should be alert to long-term complications.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disorder with fatal spontaneous evolution within 10 years after the diagnosis. Allogeneic hematopoietic stem cell transplantation (SCT) for CML has been for a long time the unique curative treatment inducing sustained molecular remission. SCT has been largely proposed when a familial HLA-matched sibling donor was available. Leukemia-free-survival at 3 years ranged from 40 to 85% after SCT. [1] [2] [3] [4] Hematological responses can also be achieved by interferon alpha and cytarabine but cytogenetic and molecular responses remain rare with these treatments. [5] [6] [7] [8] Imatinib mesylate has recently led to a dramatic change in CML management and SCT is nowadays often considered as a second-line for the vast majority of patients. However, long-term results of response, survival and eventual side effects of imatinib mesylate are currently mostly unknown. Resistance to imatinib has been reported as well as chromosomal abnormalities in Philadelphia chromosome-negative cells after imatinib treatment. 9 While there is no doubt that allogeneic SCT can cure CML in a substantial proportion of patients, there are surprisingly few studies on the long-term outcome after SCT in cured patients. Herein, we retrospectively report long-term results in our center after matched sibling SCT for CML in chronic phase and identified risk factors for outcome.
Materials and methods

Characteristics of the patients and transplantation procedure
From January 1982 to December 1998, 102 patients underwent SCT from an HLA-matched related donor for CML in chronic phase. The median length of follow-up from the date of SCT in these patients was 10 years (range: 2-21 years). Patient and transplant characteristics are summarized in Table 1 . According to EBMT score, 10 patients score was 1, 2, 3, 4 in 25, 39, 33 and five cases, respectively. Median age was 37 years old (range: 7-56 years old) at the time of transplantation. Patients received an unmanipulated bone marrow (N ¼ 98) or peripheral blood stem cell (N ¼ 4) graft. All patients received a CsA-based graftversus-host disease (GvHD) prophylaxis. CsA was progressively stopped at 6 months if patients did not experience GvHD, or earlier in the case of toxicity related to CsA. In patients with chronic GvHD, CsA discontinuation was decided by each physician according to sensitivity and toxicity. Antibiotic prophylaxis consisted of: amoxicillin, ofloxacin or pefloxacin for decontamination; trimethoprim-sulfamethoxazole three times a week for Pneumocystis carinii pneumonia (PCP) and toxoplasmosis prophylaxis; acyclovir for herpes simplex prophylaxis; and fluconazole for fungal prophylaxis. Ofloxacin was stopped after neutrophil recovery. Fluconazole was stopped after neutrophil recovery and corticosteroid discontinuation. Trimethoprim-sulfamethoxazole was continued until immunosuppressive drug withdrawal and CD4-positive lymphocyte count 40.2 Â 10 9 /l. Amoxicillin was continued for at least 10 years. Cytomegalovirus (CMV) antigenemia or plasma and urine CMV detection was performed and pre-emptive treatment was given. Patients were regularly followed by their consultants after being discharged and bcr-abl quantitative reverse-transcriptase polymerase chain reaction has been systematically performed since the 1990s.
Definitions and statistical analysis
Acute GvHD was graded according to Seattle criteria. 11, 12 Chronic GvHD was defined as none, limited and extensive according to published criteria. 11, 12 A death occurring during uncontrolled GvHD was considered as a death due to GvHD. Relapse was defined as hematological, cytogenetic or molecular. We used the methods of Kaplan and Meier to estimate median overall survival. 13 The Gray and Fine model was used to estimate the 15-year cumulative incidence of: transplantationrelated mortality (with competing risk being death from relapse), chronic GvHD (competing risk being death without GvHD), and relapse (competing risk being death not related to hematological relapse). 14 Late complications (infection, osteonecrosis, cataracts, endocrine complications, and psychological depression) were estimated with death as competing risk. Analysis focused on 15-year outcome from SCT except for second malignancies which were analyzed on 20-year outcome. The Cox proportional hazard regression model was used to test significance of covariates for outcome. 15 Risk factors for long-term survival, TRM, chronic GvHD and late complications excluded patients who died during the 100 first days after SCT (N ¼ 15). Chronic GvHD as a risk for survival was analyzed as a time-dependant /l and 450 Â 10 9 /l; acute GvHD. When groups were compared according to continuous covariates, the Mann-Whitney U-test or Kruskal-Wallis oneway ANOVA on ranks test were used for difference in medians. According to the group sizes, w 2 or Fisher's exact tests were used to compare categorical covariates. S-PLUS 2000 Professional was used for all statistical analyses.
Results
Long-term overall survival and relapse
The 15-year overall survival was 53% (95% Confidence interval (CI), 44-65) for the overall cohort with a plateau after 2.5 years ( Figure 1a ). Patients X40 years old at time of SCT had a significantly worse outcome than patients o40 years old at time of SCT (60 vs 42%, P ¼ 0.03, Figure 1b) . Among the 87 patients alive at 100 days after SCT, 17 patients died from chronic GvHD with superimposed infection, eight patients died from infection without GvHD and one patient died from hematological relapse. EBMT score, in contrast to Sokal's score at SCT, was related to long-term survival (72% (95% CI, 56-92), 54% (95% CI, 40-74), 39% (95%: 26-58) for scores 1, 2 and 3, 4, respectively, Figure 1C ). Overall survival was not dependent on the conditioning regimen (46% (95% CI, 32-65) in TBI plus Cy; 59% (95% CI, 43-81) with Bu plus Cy). Patients with previous acute GvHD of grade 0, I, II, III and IV had a survival rate of 59% (95% CI, 37-97%), 73% (95% CI, 61-87%), 71% (95% CI, 52-96), 29% (95% CI, 9-92) and 0%, respectively. Survival according to time period was not different from 1982 to 1998 (Figure 1d ). However, a significant log rank test is reached when 3-year survival from 1999 to 2003 (72%, 95% CI, 50-98) is compared to 3-year survival from 1982 to 1986 (45%, 95% CI, 29-72), P-value ¼ 0.04 (Figure 1d ). In a Cox proportional hazard model, predictors of poor outcome were: age 439 years at transplantation (RR, 2.67; 95% CI, 1.24-5.75, P ¼ 0.01), interval from diagnosis to transplantation 418 months (RR, 2.16; 95% CI, 1.03-4.55, P ¼ 0.043), no GvHD or grade III-IV acute GvHD (RR, 4.35; 95% CI, 2.04-9.10, P ¼ 0.0001) and chronic extensive GvHD as a time-dependant covariate (RR, 3.04; 95% CI, 1.40-6.61, P ¼ 0.005).
Hematological, cytogenetic or molecular relapses were low with a 15-year relapse incidence estimated at 8% (95% CI, 0.1-14). Hematological relapse occurred in two patients. Concerning molecular disease detection, 50 among 54 patients alive at last follow-up had a monitoring of molecular disease. Three patients had molecular relapse, of whom one is currently treated by DLI and two had spontaneous disappearance of the bcr-abl transcript.
Transplant-related mortality (TRM) and chronic GvHD: The 15-year TRM rate was 46% (95% CI, 37-54) with similar predictors than survival predictors because relapses Overall survival: (a) 15-year overall survival. Kaplan-Meier estimate of the 15-year survival was 53% for the overall group of patients (95% confidence interval (CI), 44-65%). (b) Influence of age on 15-year survival. Kaplan-Meier estimated survival was 60% in patients more than 40 years old (---) vs 42% in patients less than 40 years old (__) (log-rank test, P ¼ 0.016). (c) Influence of EBMT score on overall survival. KaplanMeier estimated survivals were 72% (95% CI, 56-92), 54% (95% CI, 40-74), 39% (95% :26-58) for score 1 (----), 2 (y.) and 3-4 (__), respectively. Log-rank test was significant for score 1 vs score 3-4 (P ¼ 0.006) and score 2 vs 3-4 (P ¼ 0.046). (d) Overall survival at 3 years according to time periods (1982-1986; 1987-1991; 1992-1998; 1999-2003 Long-term follow-up after allogenic transplantation M Robin et al occurred in only two patients (Table 2) . Acute GvHD had an impact on 6-month TRM (grade II-IV acute GvHD, relative risk for 6-month TRM, 19.9; 95% CI, 5.12-77.8, P ¼ 0.0001). TRM was 0, 22 (95% CI, 3-41) and 48% (95% CI,31-64) in patients alive after day 100, with no, limited and extensive GvHD, respectively.
Cumulative incidences of chronic and extensive chronic GvHD, considering death as a competing event, were 55% (95% CI, 29-50%) and 49% (95% CI, 21-41%), respectively. Significant predictors of chronic extensive GvHD were: short time to achieve 0.5 Â 10 9 /l neutrophils, previous grade II-IV acute GvHD, splenectomy before transplantation, and age at transplantation (Table 2) . Of note, irradiation in the conditioning regimen was associated with a trend to increase the risk for chronic extensive GvHD (RR, 1.82; 95% CI, 94-3.44, P ¼ 0.072).
Late complications
Infections: Among patients alive at day 100 after transplantation, bacterial infection was documented in 22 patients at a median of 9 months after SCT (range: 4-11 months) leading to a 15-year cumulative incidence rate of 37% (95% CI, 26-49) (Figure 2a ). All but one patient were receiving immunosuppressive drugs for chronic GvHD at the time of bacterial infection diagnosis. Gram-negative infections were diagnosed in 11 patients, at a median of 8 months after SCT (range 4-140 months), leading to a 15-year incidence estimated at 15% (95% CI, 7-23). Pneumococcal infections were diagnosed in six patients after SCT (median 32 months, range 10-84) with a plateau only at 7 years. Of note, all patients with pneumococcal infection were taking amoxicillin prophylaxis at time of infection (although there is no formal proof of compliance). Other infections with Gram-positive cocci occurred in five patients after SCT (median 10 months, range: 4-84 months) giving a cumulative incidence of 7.5% (95% CI, 3-13). Major risk factors for late bacterial infection are summarized in Table 3 . Extensive chronic GvHD was the only predictor by multivariate analysis.
Sixteen patients alive more than 100 days after SCT had late CMV reactivation (median of 5 months after SCT, range 4-15 months) leading to a cumulative incidence rate of late CMV reactivation of 15% (95% CI, 7-21). In all, 13 of them (81%) had had an early CMV reactivation, during the 100 first days after SCT. Late CMV reactivation occurred as second, third or fourth episodes of reactivation in eight, three and one patients, respectively. All of these patients were receiving immunosuppressive drugs for chronic GvHD at the time of CMV diagnosis. CMV reactivation was present at death in seven patients, concomitant with disseminated fungal infection in six patients.
Late Varicella-Zoster virus, Herpes simplex virus (HSV), parvovirus B19 and adenovirus infections were observed in 19 (a) Fifteen-year projected incidence for bacterial infection: 15-year cumulative incidence rate was estimated at 37% (95% CI, 26-49). Light line represents the competing event (death). (b) Twenty-year projected incidence for second malignancies: 20-year cumulative incidence rate was estimated at 21% (95, 0-55%).
Long-term follow-up after allogenic transplantation M Robin et al (23%), nine (10%), four (4.5%) and two (2%) patients, respectively. One patient died from HSV encephalitis but none of the other infections were life threatening. Hepatitis C was detected in four patients of whom two were receiving interferon for chronic viral hepatitis. Hepatitis B was detected in four patients of whom one patient was receiving interferon and another interferon plus lamivudine for chronic viral hepatitis. PCP occurred in eight patients, at a median of 8 months after SCT (range 4-13 months), leading to a 2-year PCP incidence rate of 8% (95% CI, 3-13). Of note, one patient died from PCP 15 years after SCT but no other case occurred after 13 months posttransplant. Two patients had a nonsymptomatic toxoplasmosis serological conversion after SCT.
Late disseminated aspergillosis was diagnosed in 12 patients (median 8 months after transplant, range 4-19 months) and two other patients developed a candidemia at 4 months leading to an estimated cumulative incidence of fungal infection of 16% (95% CI, 10-22). Aspergillosis incidence did not change with the date of SCT in this study (p1993, 12%,41993, 17%). All patients had pulmonary aspergillosis lesions and three patients had additional lesions (central nervous system, hepatosplenic and pleural). Three patients had leucopenia (white blood cell counts o1 Â 10 9 /l) and 10 patients were receiving corticosteroid therapy at the time of fungal infection diagnosis. Death occurred consequent to late aspergillosis diagnosis in 10 patients (83%). Acute GvHD grade II-IV logically appeared as a risk factor for fungal infection with an increased risk only for the first 6 months after SCT (RR, 7.65; 95% CI, 0.88-66, P ¼ 0.065). Significant predictors for late fungal infection were chronic GvHD, age and total number of nucleated cells infused in the graft (Table 3) .
Bone and joint complications: Osteoporosis was diagnosed in six out of 88 patients surviving more than 100 days. Osteonecrosis occurred in nine patients leading to a cumulative incidence of 12% (95% CI, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and was diagnosed at a median of 16 months after transplantation (range: 8-42 months). Half of them were surgically treated. Osteonecrosis occurred more frequently in: women (25% in women vs 15% in men), patients o40 years at the date of SCT (o40 years old, 13%, 440 years old, 7%), and patients with chronic GvHD (28 vs 9%).
Cardiac and respiratory failure: Venous phlebitis was diagnosed in one patient. Myocardial infarction occurred in one patient. Chronic pericarditis occurred in two patients without any determined cause. Five patients remained hypertensive without cyclosporine intake. Nine patients were treated for hyperlipidemia. Eight patients suffered from chronic respiratory failure of which five were attributable to GvHD-related chronic bronchiolitis.
Renal disease: In all, 10 patients had a permanent decreased creatinine clearance: 40-70 ml/min in eight patients and at 25 ml/min in two patients. No patient required chronic dialysis. One patient developed a reversible hemolytic uremic syndrome. One patient was diagnosed with an immunoglobulin-A nephropathy without impairment of renal function.
Neurological and psychiatric disturbance: Three patients had neurological complications: cerebral vasculitis (n ¼ 1), acute polyradiculonevritis (n ¼ 1), and multiple sclerosis (n ¼ 1). In all, 17 patients received medical treatment for depression leading to a cumulative incidence of depression of 18% (95% CI, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The only predictor for depression in this study was chronic extensive GvHD (33 vs 11%, P ¼ 0.034).
Thyroid failure: Hypothyroidism was diagnosed in 11 patients leading to a 15-year cumulative incidence of 11% (95% CI, 5-17).
Ocular symptoms: Cumulative incidence at 15 years of cataracts was 27% (95% CI, 11-32). Only two patients were not surgically treated. Cataracts were diagnosed at a median of 31 months after SCT (range: 4-54 months). TBI was the only significant risk factor for developing cataracts (52 vs 28%, Po0.0001).
Late malignancies: Seven patients developed a second malignancy after SCT (Figure 2b ) leading to a 20-year cumulative incidence rate of 21% (95, 0-55%). Histological types of late malignancies included melanoma (N ¼ 1), basal cell carcinoma of the skin (N ¼ 1), colon adenocarcinoma (N ¼ 1), thyroid carcinoma (N ¼ 2), squamous cell carcinoma of the mouth (N ¼ 1) and esophagus (N ¼ 1). These cancers occurred at a median of 106 months after SCT (range 13-246 Long-term follow-up after allogenic transplantation M Robin et al months). Only one patient received TBI in the conditioning regimen; five patients had chronic GvHD although four of them had a controlled GvHD with immunosuppressive withdrawal several months or years before malignancy diagnosis. No risk factors were identified in univariate analysis.
Quality of live:
Among 54 patients alive at last follow-up, 1-year performance status according to world health organization (WHO) was 0 in 32 patients, 1 in 15 patients and 2 in seven patients whereas 5-year WHO performance status was 0 in 29 patients, 1 in 12 patients and not available in 13 patients (follow-up o5 years in four patients). At 1 and 5 years after SCT, 12 and 23 of these patients, respectively, had returned to work.
Discussion
We reported here the long-term outcomes after related HLAmatched SCT for CML patients in chronic-phase. Until a few years ago, SCT was considered as the gold standard treatment in CML when an HLA-matched related donor was identified.
Overall survival after SCT, with median follow-up ranging from 3 to 7 years, is estimated from 40 to 80% with relapse and GvHD as the main causes of death. 1, 4, 16, 17 Nowadays, targeted therapies such as imatinib mesylate, which gives hematologic, cytogenetic and molecular responses, are progressively supplanting SCT as first-line therapy. However, no long-term results in patients treated by imatinib are available since the first patients were treated at the beginning of this century. It is not known if tyrosine kinase inhibitors can definitely cure patients, and even if eventually patients could stop taking this drug. Time from CML diagnosis to SCT will be increased by current management and this delay may be deleterious for the survival after SCT by increasing relapse and toxicity. In our study, patients with an increased median time from CML diagnosis to SCT had a higher risk for nonrelapse-related death in multivariate analysis (timing 418 months, relative risk, 2.34). The same question was raised one decade ago on the potential adverse effect of giving interferon before transplantation. [18] [19] [20] Currently, for young patients, physicians have to counterbalance the use of the well-tolerated tyrosine kinase inhibitors for which no long-term data exists, and a transplantation (if a related donor has been identified) with the risk of TRM but the possibility of cure. Of note, long-term complications after SCT have to be taken into account and we provide here long-term follow-up data that could be helpful for CML patient management and counseling.
Our study included patients transplanted from 1982 to 1998 and 15-year survival after SCT was estimated at 53% (95% CI, 44-65) for the overall group and 72% (95% CI, 56-92) in good risk patients (EBMT, score 1) comparable to published survival. 10 There was a substantial GvHD-related TRM whereas relapse rate was low (o10%) confirming that graft-vs-leukemia effect is correlated to GvHD. Published relapse rates after SCT are often higher than ours ranging from 0 to 20%. 4, 17, [21] [22] [23] Discrepancy between relapse rate and the relapse-related mortality recently observed is probably due to the improvement in salvage therapy after transplantation including donor lymphocyte infusion and tyrosine kinase inhibitors treatment. [24] [25] [26] [27] The use of targeted busulfan or intravenous busulfan appears promising in reducing the toxicity of the conditioning regimen. 1 We can also speculate that better results could be achieved, thanks to improvement in supportive care (antibiotics, antifungal and GvHD treatment) in patients suffering from chronic GvHD. Indeed, poor long-term survival has been reported in patients transplanted before the 1990s. 28 In our study, the main cause of death was infection related to GvHD, that is, invasive fungal infection for the majority of patients. The most common infections after SCT were bacterial, with Gram-negative infections occurring during the first year post-transplant and pneumococcal infections continuing to occur several years after transplantation without any plateau, even with penicillin prophylaxis. The main risk factor for a pneumococcal infection is extensive chronic GvHD in our study, confirmed by others. 29, 30 GvHD and corticosteroids were the major risk factors for aspergillosis, as previously described. 31 Late CMV infections were generally consecutive to an early CMV reactivation and were also associated with other infections, that is, invasive aspergillosis, reflecting an immune deficiency. Number of total nucleated cells infused in the graft and time to neutrophil recovery were risk factors for late fungal. Bittencourt et al 32 have already reported that low CD34 cell dose increased fungal infection risk.
Risk factors for bacterial infection were GvHD (relative risk, 2.38) and splenectomy before transplantation (relative risk, 3.63) in contrast to previously reported data. 33 However, splenectomy is no longer routinely performed before transplantation. Indeed, our data shows that significantly better outcomes were achieved in similar patients from 1999 to 2003. These patients were not included in our study because the main aim focused on long-term results.
The high cumulative incidence of secondary malignancies estimated at 21% at 20 years without any plateau is of concern, even though the number of patients is small. Secondary cancer included invasive cancer as well as noninvasive cancer. Three patients had a noninvasive type of cancer and one patient had a basocellular skin tumor. In the largest study involving more than 4000 CML patients who received a SCT, the 15-year incidence of invasive solid cancer using Kaplan-Meier was 6.7% (95% CI, 3.7-9.6%). 34 Long-term morbidities in our study include: life-threatening complications such as invasive cancer, cardiac or respiratory failure; and nonlife-threatening complications, which were more frequent such as cataracts, osteonecrosis and endocrinopathies. Corticosteroids, age and extensive chronic GvHD were not predictors for these late complications probably because of the small number of patients. Total body irradiation in a single dose, which is recognized to be more toxic than hyperfractionated TBI, 35, 36 was a risk factor for cataracts. Several randomized studies failed to show any advantage of TBI within conditioning regimens for CML patients whereas long-term side effects of TBI are well-known. 22, 23, 37, 38 At our center, TBI was abandoned in CML-conditioning regimens in the 1990s (last CML patient with TBI in 1993). Furthermore, patients who underwent a splenectomy and received TBI in the conditioning regimen were more susceptible to develop several late complications (42 complications in 55% of these patients vs 15% in other patients). Late morbidities may have a significant impact on quality of live. Indeed, 18% of patients have been treated for psychological depression. Of note, the only predictor of depression was the presence of extensive chronic GvHD. The majority of morbidities can be medically or surgically cured but chronic GvHD remains the most disabling complication with a psychological impact. Unfortunately, we did not compare our cohort to a control group whereas increased incidence of late malignancies has also been reported after chemotherapy without allogeneic transplantation. 39, 40 Aging of our cohort may increase the risk of some of these complications and at last follow-up, median age in our study was 46 years with 10 patients having more than 50 years. Late complications in CML patients after transplantation have to be compared to a nontransplant treatment for which no long-term data currently exists.
We conclude that allogeneic transplantation with myeloablative preparative regimen can cure at least 50-60% of patients with CML in chronic phase. Moreover, the high transplantationrelated mortality is being reduced by improvements in CML and transplantation management. Long-term complications should be identified early in order to optimize medical and surgical treatment. Until there is long-term data for imatinib, transplant remains a definitive treatment in young patients.
